We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

230 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

814% more call options, than puts

Call options by funds: $2M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

1% more funds holding

Funds holding: 227 → 230 (+3)

0.3% less ownership

Funds ownership: 6.53% → 6.24% (-0.3%)

5% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 74

19% less capital invested

Capital invested by funds: $693M → $561M (-$131M)

Holders
230
Holders Change
+3
Holders Change %
+1.32%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
70
Reduced
74
Closed
25
Calls
$2M
Puts
$219K
Net Calls
+$1.78M
Net Calls Change
-$1.41M

Top Buyers

1
BlackRock
BlackRock
New York
+$13.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
3
Northern Trust
Northern Trust
Illinois
+$3.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.21M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.89M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$29.8M
2
MC
Maverick Capital
Texas
-$12.2M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$4.33M
5
State Street
State Street
Massachusetts
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
151
American Century Companies
Missouri
$54K +$66.5K +1,117 New
CGH
152
Crossmark Global Holdings
Texas
$53K -$714 -12 -1%
KBC Group
153
KBC Group
Belgium
$52K – – –
CIBC Asset Management
154
CIBC Asset Management
Ontario, Canada
$51K – – –
FSA
155
Franklin Street Advisors
North Carolina
$50K – – –
Royal Bank of Canada
156
Royal Bank of Canada
Ontario, Canada
$50K +$28.7K +482 +86%
UBS Group
157
UBS Group
Switzerland
$48K +$9.52K +160 +19%
BG
158
Bellevue Group
Switzerland
$47K -$55.5K -933 -49%
TRCT
159
Tower Research Capital (TRC)
New York
$47K +$26K +437 +82%
PA
160
Profund Advisors
Maryland
$46K -$90K -1,513 -61%
Balyasny Asset Management
161
Balyasny Asset Management
Illinois
$46K +$57.5K +967 New
CC
162
Cipher Capital
New York
$46K +$57.5K +967 New
Handelsbanken Fonder
163
Handelsbanken Fonder
Sweden
$45K – – –
Mariner
164
Mariner
Kansas
$45K +$55.4K +932 New
TSS
165
Two Sigma Securities
New York
$44K -$46.7K -785 -46%
AIP
166
Ameritas Investment Partners
Nebraska
$43K – – –
XSC
167
X-Square Capital
Puerto Rico
$42K – – –
Mackenzie Financial
168
Mackenzie Financial
Ontario, Canada
$38K -$2.02K -34 -4%
SCM
169
Shelton Capital Management
Colorado
$38K – – –
Verition Fund Management
170
Verition Fund Management
Connecticut
$38K – – –
Nisa Investment Advisors
171
Nisa Investment Advisors
Missouri
$36K -$3.69K -62 -8%
Aberdeen Group
172
Aberdeen Group
United Kingdom
$36K – – –
AWA
173
Arete Wealth Advisors
Illinois
$35K +$43.6K +733 New
Connor, Clark & Lunn Investment Management (CC&L)
174
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$34K -$108K -1,808 -72%
STAS
175
Strong Tower Advisory Services
Minnesota
$34K -$4.76K -80 -10%
5 6
7
8 9

NKTR Hedge Fund Activity: Q3 2022 in Review

230 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $693M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.

  • 230 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
  • The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2022.